AMICUS THERAPEUTICS, INC. — Director's Dealing 2022

Jan 7, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2022-01-05

Reporting Person: Crowley John F (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-05	Common Stock	S	63543	$12.1826	Disposed	655131	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	64895	Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: Comprised of 46,910 shares received from the 2019 PRSU grant, awarded for exceeding the Galafold revenue goal for the applicable measurement period, and 16,333 shares received from the 2018 annual grant, the receipt of which were deferred by Mr. Crowley until January 1, 2022.

F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.95 to $12.59 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.